Reduced-Intensity Regimen Before Allogeneic Transplant for Patients With Relapsed Non-Hodgkin's or Hodgkin's Lymphoma
Public ClinicalTrials.gov record NCT00057954. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Study of Reduced Intensity Allogeneic Bone Marrow Transplantation for the Treatment of Relapsed Non-Hodgkin and Hodgkin Lymphoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
RATIONALE: Photopheresis allows patient white blood cells to be treated with ultraviolet (UV) light and drugs outside the body to inactivate T cells. Pentostatin may suppress the immune system and reduce the chance of developing graft-versus-host disease (GVHD) following bone marrow transplantation. Combining photopheresis with pentostatin and total-body irradiation may be effective in killing cancer cells before bone marrow transplantation. PURPOSE: This phase II trial is studying how well giving photophoresis together with pentostatin and total-body irradiation as a reduced-intensity regimen before allogeneic bone marrow transplantation works in treating patients with relapsed non-Hodgkin's or Hodgkin's lymphoma.
Study identification
- NCT ID
- NCT00057954
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 6 participants
Conditions and interventions
Conditions
Interventions
- Extracorporeal Photopheresis Procedure
- Pentostatin Drug
- Total body irradiation (TBI) Radiation
- Allogeneic bone marrow transplantation Procedure
- Cyclosporin (CSA) Drug
- Mycophenolate mofetil (MMF) Drug
- Methotrexate (MTX) Drug
Procedure · Drug · Radiation
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 8, 2005
- Primary completion
- Mar 31, 2008
- Completion
- Apr 30, 2011
- Last update posted
- Jun 27, 2023
2005 – 2011
United States locations
- U.S. sites
- 19
- U.S. states
- 6
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Aurora Presbyterian Hospital | Aurora | Colorado | 80012 | — |
| Boulder Community Hospital | Boulder | Colorado | 80301-9019 | — |
| Penrose Cancer Center at Penrose Hospital | Colorado Springs | Colorado | 80933 | — |
| Porter Adventist Hospital | Denver | Colorado | 80210 | — |
| Presbyterian - St. Luke's Medical Center | Denver | Colorado | 80218 | — |
| St. Joseph Hospital | Denver | Colorado | 80218 | — |
| Rose Medical Center | Denver | Colorado | 80220 | — |
| CCOP - Colorado Cancer Research Program | Denver | Colorado | 80224-2522 | — |
| Swedish Medical Center | Englewood | Colorado | 80110 | — |
| St. Mary's Regional Cancer Center at St. Mary's Hospital and Medical Center | Grand Junction | Colorado | 81502 | — |
| Sky Ridge Medical Center | Lone Tree | Colorado | 80124 | — |
| Hope Cancer Care Center at Longmont United Hospital | Longmont | Colorado | 80502 | — |
| St. Mary - Corwin Regional Medical Center | Pueblo | Colorado | 81004 | — |
| North Suburban Medical Center | Thornton | Colorado | 80229 | — |
| Mayo Clinic - Jacksonville | Jacksonville | Florida | 32224 | — |
| Tufts-NEMC Cancer Center | Boston | Massachusetts | 02111 | — |
| Mayo Clinic Cancer Center | Rochester | Minnesota | 55905 | — |
| Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School | New Brunswick | New Jersey | 08903 | — |
| Case Comprehensive Cancer Center | Cleveland | Ohio | 44106-5065 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00057954, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 27, 2023 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00057954 live on ClinicalTrials.gov.